19:54 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Esperion hypercholesterolemia candidate meets in fifth and final Phase III

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) as monotherapy met the primary endpoint of reducing LDL-C in the Phase III CLEAR Wisdom (1002-047) trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
18:51 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Esperion combo lowers LDL-C in Phase III for high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
19:45 , Aug 27, 2018 |  BC Extra  |  Clinical News

Esperion combo lowers LDL-C in high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
16:08 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Esperion's bempedoic acid combo meets in Phase II for hypercholesterolemia

Esperion Therapeutics Inc. (NASDAQ:ESPR) reported top-line data from the Phase II 1002-038 trial in 63 patients with hypercholesterolemia showing that the once-daily combination of 180 mg bempedoic acid (ETC-1002)/10 mg Zetia ezetimibe plus 20 mg...
22:04 , Aug 10, 2017 |  BC Extra  |  Financial News

Esperion raises $151.9M for CVOT

Esperion Therapeutics Inc. (NASDAQ:ESPR) raised $151.9 million late Wednesday through the sale of 3.1 million shares at $49 in a follow-on underwritten by Jefferies, Cowen, UBS, JMP, Stifel and Needham. The price is a 6%...
00:16 , Aug 9, 2017 |  BC Extra  |  Clinical News

Esperion to raise funds after reporting bempedoic acid LDL-C data

Esperion Therapeutics Inc. (NASDAQ:ESPR) proposed to raise $150 million in a follow-on after market close on Tuesday following its announcement earlier in the day that oral bempedoic acid (ETC-1002)/ Zetia ezetimibe plus Lipitor atorvastatin met...